Drug Profile
Research programme: protein tyrosine phosphatase inhibitors - Metabasis Therapeutics
Latest Information Update: 13 Nov 2009
Price :
$50
*
At a glance
- Originator Cengent Therapeutics
- Class Small molecules
- Mechanism of Action Protein-tyrosine-phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 29 Jun 2006 Metabasis Therapeutics acquired from Cengent's note holders all of the assets of Cengent pertaining to PTP-1B programme for metabolic diseases
- 04 Sep 2003 Preclinical data from a media release have been added to the Diabetes pharmacodynamics section
- 26 May 2003 The programme is available for licensing (http://www.cengent.com)